Lynparza, AstraZeneca's DNA damage repair drug, has been approved by the EU as a first-line treatment preventing the return of ovarian cancer after initial chemotherapy treatment.

Niall Martin, CEO of Arix portfolio company Artios, played a key role in the discovery and early development of Lynparza while CEO of KuDOS Pharma, which was acquired by AstraZeneca in 2005.

Read more about Lynparza and Niall Martin's role in its development in Labiotech's article here.

Image: Shuttershock via Labiotech